Search research articles
Contact Us
Filters
Showing results (231-240 of 336) with videos related to
Page
of 34
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 11, 2023
Efficacy of chemotherapy according to <i>BRCA</i> status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse
Flora Brouillard-Saby, Caroline Saint-Martin, Isabelle Ray-Coquard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 25, 2013
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study
Ignace B Vergote, Antonio Jimeno, Florence Joly, et al.
Urologic Oncology
|
December 17, 2015
Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era
Gwenaelle Gravis, Brice Chanez, Lisa Derosa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 25, 2010
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
Andreas du Bois, Jørn Herrstedt, Anne-Claire Hardy-Bessard, et al.
Gynecologic Oncology
|
July 1, 2025
NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer
Kristina Lindemann, Dominique Berton, Jalid Sehouli, et al.
Gynecologic Oncology
|
February 27, 2024
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer
Felicia Roncolato, Madeleine T King, Rachel L O'Connell, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
December 18, 2017
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
Madeleine T King, Martin R Stockler, Rachel L O'Connell, et al.
Gynecologic Oncology
|
July 27, 2020
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)
Patrick Robelin, Michel Tod, Olivier Colomban, et al.
Bulletin Du Cancer
|
April 4, 2012
[PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved]
Isabelle Ray-Coquard, Franck Chauvin, Eric Leblanc, et al.
Gynecologic Oncology
|
November 18, 2018
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial
Clémence Romeo, Florence Joly, Isabelle Ray-Coquard, et al.
Page
of 34
Search research articles
Search
Showing results (231-240 of 336) with videos related to
Sort By:
Page
of 34
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 11, 2023
Efficacy of chemotherapy according to <i>BRCA</i> status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse
Flora Brouillard-Saby, Caroline Saint-Martin, Isabelle Ray-Coquard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 25, 2013
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study
Ignace B Vergote, Antonio Jimeno, Florence Joly, et al.
Urologic Oncology
|
December 17, 2015
Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era
Gwenaelle Gravis, Brice Chanez, Lisa Derosa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 25, 2010
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
Andreas du Bois, Jørn Herrstedt, Anne-Claire Hardy-Bessard, et al.
Gynecologic Oncology
|
July 1, 2025
NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer
Kristina Lindemann, Dominique Berton, Jalid Sehouli, et al.
Gynecologic Oncology
|
February 27, 2024
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer
Felicia Roncolato, Madeleine T King, Rachel L O'Connell, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
December 18, 2017
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
Madeleine T King, Martin R Stockler, Rachel L O'Connell, et al.
Gynecologic Oncology
|
July 27, 2020
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)
Patrick Robelin, Michel Tod, Olivier Colomban, et al.
Bulletin Du Cancer
|
April 4, 2012
[PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved]
Isabelle Ray-Coquard, Franck Chauvin, Eric Leblanc, et al.
Gynecologic Oncology
|
November 18, 2018
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial
Clémence Romeo, Florence Joly, Isabelle Ray-Coquard, et al.
Page
of 34